Drug Discovery & DDS– category –
-
McKinsey Report: Generative AI and Foundation Models Revolutionize Biopharma R&D Workflow, Accelerating Molecular Design and Antibody Engineering
McKinsey Unknown Overview A McKinsey report highlights that generative AI and foundation models are revolutionizing biopharma R&D workflows. These AI models design novel molecular structures, experimental hypotheses, and synthetic pa... -
AI-Driven JAM Platform Designs Molecular Binders Beyond GPCR Antibody Generation: Achieves High Hit Rates for CXCR7 and Claudin-4 Targets, AI-Discovered Drugs Advance to Phase IIa
Pharma Focus Asia Unknown Overview The AI-driven JAM platform has surpassed traditional GPCR antibody generation methods, predicting previously overlooked molecular binding interactions. JAM computationally designed binders for multi-tra... -
Oral GLP-1 Agonist Semaglutide Success Drives Peptide Drug Discovery Transformation: AI Design, Unnatural Amino Acids, and Nanocarriers Enhance Oral Bioavailability
Bhunia Lab Unknown Overview While peptide therapeutics have advanced significantly, oral delivery remains a challenge. The success of oral semaglutide demonstrates how chemical modifications like amino acid substitutions and fatty acid a... -
Ionis’ ASO Therapy Zilganersen Awaits FDA Approval for Alexander Disease: Achieves Primary Endpoints and Granted Priority Review
BioXconomy USA Overview Ionis Pharmaceuticals' antisense oligonucleotide (ASO), zilganersen, is awaiting FDA approval for the ultra-rare neurological disorder, Alexander disease. The pivotal Phase 1-3 trial (NCT04849741) met its primary ... -
Antibody-Drug Conjugates (ADCs) Show Promise for Epithelioid Hemangioendothelioma (EHE) Treatment: Highlighted at ASCO 2026
EHE Foundation USA Overview Antibody-drug conjugates (ADCs) are gaining significant attention as a promising emerging strategy for treating epithelioid hemangioendothelioma (EHE), a rare and challenging cancer. ADCs deliver potent anti-c... -
BMS Molecular Glue Mezigdomide Combination Therapy Transforms Oncology: Achieves 52% Reduction in Progression or Death Risk in Phase 3 Multiple Myeloma Trial
PMLiVE Unknown Overview Targeted protein degraders (TPDs), specifically PROTACs and molecular glues, are rapidly advancing in oncology. At ASCO, Bristol Myers Squibb (BMS) announced Phase 3 results showing their molecular glue, Mezigdomi... -
Constructive Bio Develops Oral Peptide Pipeline with Novel Membrane Permeability via Unnatural Amino Acids, Advancing ADCs with Genetic Code Expansion for Injectable-to-Oral Shift
Constructive Bio Unknown Overview Constructive Bio is developing a pipeline of oral peptide therapeutics using unnatural amino acids to enable oral bioavailability for drugs previously requiring injection. These engineered peptides featu... -
Foundation Models and Generative AI Reshape Molecular Science: Data-Centric Learning Boosts Virtual Screening Accuracy and Molecular Generation Control
Curate ND USA Overview Foundation models and generative AI are transforming molecular prediction, exploration, and design across chemistry, biology, and materials science. This research developed data-centric learning methods and molecul... -
Variational AI Accelerates Generative AI Drug Discovery on AWS with Enki™ Platform: Resolving Clinical Failure’s Root Cause Through Multi-Parameter Optimization
AWS Canada Overview Variational AI, leveraging AWS, is redesigning drug discovery as a generative AI problem to create innovative drug molecules. Its Enki™ platform, trained on vast datasets of public, approved, and patented drugs, aims ... -
FDA Approves Expanded Indication for Ionis’ ASO Tryngolza in Severe Hypertriglyceridemia, Achieving <500 mg/dL TG Levels in 86% of Patients
Fierce Pharma USA Overview The FDA has approved an expanded indication for Ionis Pharmaceuticals’ antisense oligonucleotide (ASO) Tryngolza (olezarsen) for severe hypertriglyceridemia. Clinical trials demonstrated remarkable efficacy, wi...
